What is the recommended nitrofurantoin dosing for uncomplicated urinary tract infection in adults, including adjustments for renal function, pregnancy, and in children?

Nitrofurantoin Dosing for UTI

For uncomplicated cystitis in adults, prescribe nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days. This is the first-line recommendation with an A-I level evidence rating, demonstrating 93% clinical efficacy and 88% microbiological efficacy 1.

Adult Dosing by Clinical Scenario

Uncomplicated Cystitis (Lower UTI)

• Standard dose: 100 mg twice daily for 5 days 1, 2, 3
• Alternative regimen: 100 mg twice daily for 7 days (equally effective but longer duration) 1
• Clinical efficacy: 88-93% cure rate 1
• Microbiological efficacy: 86-92% bacterial eradication 1

The 5-day regimen is preferred because it achieves equivalent outcomes to the 7-day course while minimizing antibiotic exposure 1. A 2018 randomized trial demonstrated that 5-day nitrofurantoin was superior to single-dose fosfomycin, with 70% vs 58% clinical resolution at 28 days 4.

Pyelonephritis (Upper UTI)

Nitrofurantoin is NOT recommended for pyelonephritis 3. The drug achieves high urinary concentrations but minimal tissue penetration, making it ineffective for kidney infections 5. Use fluoroquinolones (5-7 days) or β-lactams (7 days) instead 2, 3.

Renal Function Adjustments

Key Threshold Change

• Avoid if CrCl <30 mL/min (updated from previous <60 mL/min threshold) 6
• Safe to use with CrCl 30-60 mL/min: The 2015 Beers Criteria revision allows use in moderate renal impairment based on safety and efficacy data 6
• Rationale: Adequate urinary concentrations are still achieved with CrCl ≥30 mL/min 3, 6

Important Caveat

While nitrofurantoin can be used with CrCl 30-60 mL/min, monitor closely for peripheral neuropathy, which is more common in renal impairment 7. Conditions like anemia, diabetes, electrolyte imbalance, and vitamin B deficiency further increase neuropathy risk 7.

Pregnancy Considerations

Nitrofurantoin is safe in pregnancy except near term 5:

• Safe: Throughout most of pregnancy for uncomplicated cystitis
• Avoid: At term (≥38 weeks) and during labor due to theoretical risk of hemolytic anemia in newborns with G6PD deficiency 7
• Dose: Same as non-pregnant adults (100 mg twice daily for 5 days)

The guidelines specifically exclude pregnant women from their scope 1, but nitrofurantoin remains one of the few antibiotics with established safety data in pregnancy 5.

Pediatric Dosing

The provided evidence does not contain specific pediatric dosing recommendations. The guidelines explicitly focus on premenopausal, nonpregnant women 1. Pediatric UTI management requires separate clinical guidance not addressed in these sources.

Special Populations

Elderly Patients

• Use 50 mg daily for prophylaxis rather than 100 mg to reduce adverse effects 8
• Treatment dose remains 100 mg twice daily for acute infection
• Monitor closely: Elderly patients have higher risk of pulmonary toxicity with prolonged use (>6 months) 7
• Avoid chronic use: Risk of irreversible pulmonary fibrosis increases with duration 7

Prophylaxis for Recurrent UTI

• Dose: 50 mg once daily (preferred over 100 mg) 8
• Evidence: 50 mg has equivalent efficacy to 100 mg with better safety profile—lower rates of cough (HR 1.82), dyspnea (HR 2.68), and nausea (HR 2.43) with 100 mg 8

Comparative Effectiveness

Nitrofurantoin demonstrates equivalent or superior efficacy compared to alternatives:

• vs. TMP-SMX (3 days): Equivalent clinical cure (90% each) and microbiological cure (92% vs 91%) 1
• vs. Fosfomycin (single dose): Superior—70% vs 58% clinical resolution at 28 days 4
• vs. Fluoroquinolones (3 days): Comparable efficacy (93% vs 95%) with less collateral damage 1

Critical Safety Warnings

Pulmonary Toxicity

• Chronic reactions: Occur with continuous treatment ≥6 months 7
• Manifestations: Malaise, dyspnea, cough, diffuse interstitial pneumonitis/fibrosis 7
• Risk: May be permanent even after stopping therapy if not recognized early 7
• Action: Discontinue immediately if pulmonary symptoms develop

Peripheral Neuropathy

• Risk factors: CrCl <60 mL/min, anemia, diabetes, electrolyte imbalance, vitamin B deficiency 7
• Severity: May become severe or irreversible; fatalities reported 7
• Prevention: Avoid in patients with multiple risk factors

Hepatotoxicity

• Rare but serious: Hepatitis, cholestatic jaundice, chronic active hepatitis, hepatic necrosis 7

Why Nitrofurantoin is First-Line

1. Minimal resistance: Interferes with multiple bacterial cellular functions, making resistance uncommon 9, 10
2. Minimal collateral damage: High urinary concentration with low serum/tissue levels preserves gut microbiome 10
3. Broad coverage: Remains active against multidrug-resistant uropathogens including ESBL-producing E. coli 5, 9
4. Spares fluoroquinolones: Reserves systemically active agents for more serious infections 1

Common Pitfalls to Avoid

1. Do not use for pyelonephritis or febrile UTI—inadequate tissue penetration 3, 5
2. Do not use with CrCl <30 mL/min—ineffective and increased toxicity risk 6
3. Do not prescribe for chronic suppression in elderly without careful risk-benefit assessment—pulmonary fibrosis risk 7, 8
4. Do not use near term in pregnancy—hemolytic anemia risk in G6PD-deficient newborns 7
5. Do not continue if pulmonary or neurologic symptoms develop—may become irreversible 7